Bioscript Data Insights
Bioscript Data Insights
Empowering evidence-based decisions in complex, competitive environments
Our Bioscript Data Insights (BDI) capability integrates data and analysis into our strategic recommendations, to enable you to act with agility.
See how BDI was deployed to help build a Medical Science Liaisons (MSLs) business case for senior leadership.
Case study
Deploying BDI to help demonstrate return on investment and build an MSL business case for senior leadership
The challenge
We partnered with the global medical affairs team at a biotech company. The team sought to secure additional budget to hire MSLs in three new territories, and to do so, wanted to accurately assess the impact and resonance of the team’s efforts.
Doing so would support budget discussions and enable investment in the team’s research and communications activities.
The solution
We worked with the medical team to apply BDI’s measurement capabilities, to quantify and qualify the impact of the team’s activities. Creating a comprehensive overview of this, the team was able to present this back to senior management and truly demonstrate the ROI the business received as a result of its efforts.
The result
The measurement-driven overview was fundamental in securing increased budget, thus enabling the business to appoint three MSLs in new territories. By measuring changes in our client’s landscape, we were able to prove their programme was delivering value to the organisation.
Ahead of the American Society of Hematology annual meeting (ASH), we used BDI to create a customised data visualisation of key competitors in attendance, abstracts, topics and themes likely to be discussed, ensuring the client could maximise their time and resources at ASH.
A breadth of capabilities
Our global capabilities cover strategic planning, scientific communications, data insights, market access consultancy and regulatory medical writing. This cross-discipline approach means we can help you navigate across internal departments, external stakeholder groups and international markets at pace.
